Format

Send to

Choose Destination
Ther Adv Respir Dis. 2016 Jun;10(3):183-93. doi: 10.1177/1753465816636557. Epub 2016 Mar 4.

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Author information

1
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo 11665, Egypt omar.abdelrhman@med.asu.edu.eg.
2
Medical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Abstract

BACKGROUND:

A meta-analysis of the risk of pneumonitis associated with the use of immune checkpoint inhibitors in cancer patients has been conducted.

METHODS:

Eligible publications included randomized trials of cancer patients on immune checkpoint inhibitors, describing events of all-grade and high-grade pneumonitis.

RESULTS:

After exclusion of noneligible citations, a total of 11 clinical trials were eligible for the meta-analysis. The odds ratio was 3.96 [95% confidence interval (CI): 2.02-7.79; p < 0.0001] for all-grade pneumonitis and 2.87 (95% CI: 0.90-9.20; p = 0.08) for high-grade pneumonitis. Moreover, the odds ratio of all-grade pneumonitis with a nivolumab/ipilimumab combination versus ipilimumab monotherapy was 3.68 (95% CI: 1.59-8.50; p = 0.002) and, for high-grade pneumonitis, it was 1.86(95% CI: 0.36-9.53; p = 0.46). Subgroup analysis did not reveal a difference between lung cancer patients and other cancer patients in the risk of pneumonitis.

CONCLUSIONS:

Our analysis provided evidence that the use of immune checkpoint inhibitors is associated with an increased risk of all-grade pneumonitis compared with chemotherapy or placebo controls.

KEYWORDS:

NSCLC; ipilimumab; nivolumab; pembrolizumab; pneumonitis

PMID:
26944362
PMCID:
PMC5933609
DOI:
10.1177/1753465816636557
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center